Active substanceInterferon alfa-2bInterferon alfa-2b
Similar drugsTo uncover
  • Altevir®
    solution for injections 
    FARMAPARK, LLC     Russia
  • Alpharone®
    lyophilizate nazal. 
    NPP FARMAKLON, LLC     Russia
  • Viferon®
    suppositories rect. 
    FERON, LLC     Russia
  • Grippferon®
    spray nazal. 
    FIRN M, ZAO     Russia
  • Grippferon®
    drops nazal. 
    FIRN M, ZAO     Russia
  • Interferal®
    aerosol locally 
  • Interferal®
    lyophilizate for injections 
  • Intron® A
    solution in / in PC 
  • Layfferon®
    lyophilizate w / m d / eye with / konyuk. 
    VECTOR-MEDICA, CJSC     Russia
  • Layfferon
    lyophilizate w / m d / eye with / konyuk. 
    VECTOR-MEDICA, CJSC     Russia
  • Layfferon®
    solution w / m d / eye with / konyuk. 
    VECTOR-MEDICA, CJSC     Russia
  • Realdiron®
    lyophilizate w / m PC 
  • Realdiron®
    lyophilizate w / m PC 
  • Reaferon-EU
    lyophilizate locally for injections 
    VECTOR-MEDICA, CJSC     Russia
  • Reaferon-EU-Lipint
    lyophilizatesuspension inwards 
    VECTOR-MEDICA, CJSC     Russia
  • Reaferon-EU-Lipint
    lyophilizatesuspension inwards 
    VECTOR-MEDICA, CJSC     Russia
  • Reaferon-LIPINT®
    capsules inwards 
    VECTOR-MEDICA, CJSC     Russia
  • Dosage form: & nbspaerosol for topical use
    Composition:One bottle (10 ml) of the preparation contains 100 000 ME of interferon alpha-2b human recombinant,auxiliary substances: sodium hydrophosphate dodecahydrate 0.018 g, sodium dihydrogen phosphate dihydrate 0.013 g, sodium chloride 0.08 g, disodium edetate 0.0067 g, dextran [m.m., 50,000-70000] 0.00017 g, polysorbate-80-0.0005 g, alpha-tocopherol acetate-0.00005 g, benzalkonium chloride -0.0001 g, benzoic acid 0.005 g, ethanol 95% -0.05 ml, purified water 9.81 ml, propellant nitrogen - from 0.1 to 0.2 g.
    Description:Transparent colorless liquid.
    Pharmacotherapeutic group:Cytokine
    ATX: & nbsp

    L.03.A.B.05   Interferon alfa-2b

    Pharmacodynamics:The active substance of Interferal ® is an interferon alpha-2b human recombinant synthesized by the strain of Escherichia coli BL 21 (DE 3) [pAYC-ET- (hIFN-α2b) -lacI], in the genetic apparatus of which the human leukocyte interferon alpha-2b gene . Like all interferons, Interferal® has antiviral, antitumor, immunomodulating activity. It penetrates into the systemic bloodstream through the mucous membrane of the respiratory tract, it undergoes decay in the body, is partially excreted, mainly through the kidneys. Local application for the treatment of viral infections provides a high concentration of interferon in the focus of inflammation.
    Indications:Interferal ® is used to prevent and treat influenza and other acute respiratory viral diseases (ARVI) in adults.
    Contraindications:Individual intolerance, severe forms of allergic diseases, autoimmune diseases, pregnancy, the period of breastfeeding, children under 18 years.
    Pregnancy and lactation:Interferal ® is not recommended for use during pregnancy and during breastfeeding.
    Dosing and Administration:

    Before use, a safety cap is removed from the balloon, a spray head is inserted, the free end of which is injected alternately into the common nasal passages and briefly squeezed onto the spray head (less than 1 second), with a single dose of approximately 2,000 to 3,000 IU.

    For the treatment of influenza and acute respiratory viral infection, Interferal®, an aerosol for topical application of 100,000 IU, is administered 7 times a day, every 2 hours (daily dose is up to 20,000 IU) in the first two days of the disease, then 3 times a day (daily dose - up to 10 000 ME) for five days. If symptoms persist for more than 5 days, consult a physician. Interferon therapy is performed against the background of traditional symptomatic therapy.

    For the prevention of OPVI and influenza: when in contact with the patient and during hypothermia, the drug is used in a single dose 2 times a day for 5-7 days. If necessary, preventive courses are repeated; with a seasonal increase in the incidence of the drug administered in the morning after 1 -2 days.

    After each injection, it is recommended to massage the wings of the nose with your fingers for several minutes to distribute the drug evenly in the nasal cavity.

    Side effects:Possible local allergic reactions - mild burning, itching in the nose, sneezing. In such cases, the drug is discontinued. If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.
    Overdose:Cases of overdose have not been registered to date.
    Interaction:
    It is not recommended simultaneous use of intranasal vasoconstrictor drugs (contributes to the additional drying of the nasal mucosa).
    Effect on the ability to drive transp. cf. and fur:
    The drug does not affect the ability to drive vehicles and service moving machinery.
    Form release / dosage:
    Aerosol for topical application, 100 000 ME.
    Packaging:
    Aerosol for topical use, 100 000 ME (10 ml) in an aerosol container of aluminum or glass with a protective polymer coating with a continuous valve, a sprayer and a safety cap with instructions for use in a pack of cardboard.
    Storage conditions:

    The preparation is stored and transported at a temperature of 2 to 8 ° C.

    Keep out of the reach of children.

    The container can not be opened, the contents are under pressure.

    Protect from falls, shocks and direct sunlight.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-001989
    Date of registration:30.01.2013 / 16.12.2016
    Expiration Date:30.01.2018
    Date of cancellation:2018-01-30
    The owner of the registration certificate:GosNII OCHB FMBA, FSUE GosNII OCHB FMBA, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp27.10.2017
    Illustrated instructions
      Instructions
      Up